Treatment of Fragile-X Associated Tremor/Ataxia Syndrome (FXTAS) With Allopregnanolone
Completed
Randi J. Hagerman, MD
Phase 2
2015-10-01
The purpose of this study is to examine the safety and efficacy of Allopregnanolone as a
possible treatment for symptoms of Fragile X-associated Tremor/Ataxia Syndrome (FXTAS).
Treatment of Fragile-X Associated Tremor/Ataxia Syndrome (FXTAS) With Allopregnanolone
Completed
University of California, Davis
Phase 2
2015-10-01
The purpose of this study is to examine the safety and efficacy of Allopregnanolone as a
possible treatment for symptoms of Fragile X-associated Tremor/Ataxia Syndrome (FXTAS).
A Study to Assess the Safety of Brexanolone in the Treatment of Adolescent Female Participants With Postpartum Depression (PPD)
Completed
Sage Therapeutics
Phase 3
2018-05-17
This is a multi-center study evaluating the safety, tolerability, and pharmacokinetics of
brexanolone in the treatment of adolescent female participants with postpartum depression.
A Study to Evaluate Multimodal Neuroimaging Parameters in Women With Postpartum Depression Who Are Receiving ZULRESSO™ (Brexanolone)
Withdrawn
Sage Therapeutics
Phase 4
2020-02-01
In this Phase 4 study, women who have been prescribed commercial ZULRESSO™ (brexanolone) by a
physician as standard of care for postpartum depression (PPD) and who are planning to receive
the infusion per United States Prescribing Information (USPI) at a Risk Evaluation and
Mitigation Strategy (REMS)-certified healthcare center are being asked to participate to
collect data on multimodal neuroimaging parameters in order to evaluate the relationship
between changes in depressive symptoms and changes in neuroimaging parameters.
A Study of Brexanolone for Acute Respiratory Distress Syndrome Due to COVID-19
Terminated
Sage Therapeutics
Phase 3
2020-12-18
The purpose of this study is to evaluate the efficacy and safety of brexanolone in
participants on ventilator support for acute respiratory distress syndrome (ARDS) due to
COVID-19.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
